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Abstract: This study examined the inter-model agreement between the Fitbit Flex (FF) and FF2
in estimating sedentary behavior (SED) and physical activity (PA) during a free-living condition.
33 healthy adults wore the FF and FF2 on non-dominant wrist for 14 consecutive days. After
excluding sleep and non-wear time, data from the FF and FF2 was converted to the time spent
(min/day) in SED and PA using a proprietary algorithm. Pearson’s correlation was used to evaluate
the association between the estimates from FF and FF2. Mean absolute percent errors (MAPE) were
used to examine differences and measurement agreement in SED and PA estimates between FF
and FF2. Bland-Altman (BA) plots were used to examine systematic bias between two devices.
Equivalence testing was conducted to examine the equivalence between the FF and FF2. The FF2 had
strong correlations with the FF in estimating SED and PA times. Compared to the FF, the FF2 yielded
similar SED and PA estimates along with relatively low measurement discords and did not have
significant systematic biases for SED and Moderate-to-vigorous PA estimates. Our findings suggest
that researchers may choose FF2 as a measurement of SED and PA when FF is not available in the
market during the longitudinal PA research.
Keywords: sedentary behavior; physical activity; inter-device agreement; epidemiological
1. Introduction
It is no secret that regular physical activity (PA) provides many health benefits. Benefits
include, but are not limited to, reduced hypertension, obesity, type-2 diabetes, as well
as lower medical costs across the lifespan [1–3]. Objective and accurate self-monitoring
of PA can effectively facilitate the engagement of adequate amounts and intensities [4].
Recently, consumer-based activity monitors, like Fitbit, have been widely used for assisting
individuals’ self-monitoring of PA and sleep. These activity monitors track time spent in PA
and sedentary behavior (SED) and, energy expenditure (EE), and daily steps with efficiency
and relatively low cost [5–8]. Built-in accelerometers in consumer activity monitors can
estimate the frequency and intensity of the user’s PA by calculating the acceleration of the
user’s bodily movement primarily based on the proprietary algorithm [9,10] Furthermore,
most consumer activity monitors are typically worn on the wrist and connected to a
mobile application, which increase users’ adherence to wearing time. With their popularity,
capability, and cost-efficiency, consumer-based activity monitors have great potential for
being effective tools that assess SED and PA in large cohorts within both clinical and
research settings.
Fitbit (San Francisco, CA, USA) is a leading manufacturer of consumer-based activity
monitors in the health and fitness market. Recent data showed that there were more than
29 million active Fitbit users in 2019 [11]. Fitbit devices have been increasingly used by re-
searchers as a measurement or intervention tool of PA due to its inexpensive cost, real-time
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tracking, user-friendly dashboard and app, and its validity and reliability for estimating EE,
step counts, activity intensity, sleep quality, and other personal metrics (e.g., socialization
features) [8,12–18]. The Fitbit Flex™ (FF) is a wrist-worn activity monitor. It has been
a popular model due to its competitive cost and simplicity of use. Recent studies have
reported FF could provide comparable estimates of total EE, SED and total PA (TPA) time
compared with other objective measures, such as research-based accelerometers, indirect
calorimetry, and direct observation [5,19,20]. The previous study by Bai et al., showed that
the FF similarly estimated total EE (mean bias: 20.4 kcal (6% difference)) compared with
indirect calorimetry during an 80-min protocol of semi-structured activities [5]. Addition-
ally, Redenius et al., reported that the FF had an acceptable measurement error (6.8% mean
absolute percent error) in estimating SED compare to ActiGraph GT3X+ accelerometer
under free-living condition [20]. Another study revealed that the FF accurately classified
TPA in comparison with direct observation in children (area under the receiver operating
curve: 0.92) [19]. These results indicate that FF is capable of being an assessment tool for
PA surveillance in clinical and epidemiological research.
Despite the advantageous features of Fitbit, the manufacturer’s frequent updates
may cause variation in its measurement properties. Due to the nature of the competitive
commercial market, Fitbits updates occur much more frequently than those of research-
grade accelerometers. Nevertheless, the National Institute of Health included Fitbit as a
device of choice for a recently launched large scale longitudinal study (target N ≥ 1 million)
called All of Us Research Program. This study aims to improve health and prevent
disease using the data available via wearable technologies such as Fitbit. In the All
of Us Research Program, participants provide the data collected by Fitbit to the study
regardless of the model of Fitbit they use. This suggests the shorter lifespan of Fitbit
models may not limit their utilization in longitudinal studies if the inter-device reliability
is high across model generations.
The Fitbit Flex™ 2 (FF2) is the FF’s second generation with some obvious upgrades.
The FF2 has improved battery life and is 30% lighter and smaller than the FF. Additionally,
FF2 has a waterproof feature, which improves usability. Although the manufacturer has
stated improved features for the FF2, the consistency between the FF and FF2 in activity
monitoring, specifically the estimates of SED and PA, have not yet been examined by
data-driven research. Therefore, the primary purpose of this study was to examine the
inter-device agreement between the FF and FF2 for estimating time spent SED and PA in
free-living conditions. The outcomes of this study will provide information for the potential
cross-utilization of the FF and FF2 in PA surveillance and epidemiological research.
2. Materials and Methods
2.1. Participants
A non-probability convenience sample of 33 adult volunteers participated in this
study. We excluded any participants who were under 18 years-old, physically disabled,
pregnant, or unable to participate in regular PA as recommended by a physician associated
with this study. This study was approved by the University Institutional Review Board,
and all participants provided written consent to participate prior to data collection.
2.2. Instruments
The FF and the FF 2 (Fitbit, Inc., San Francisco, CA, USA) were used in this study.
Both devices are light (FF: 14.6 g and FF2: 10.2 g), small (FF: 2.09 × 0.14 cm and FF2:
2.05 × 0.1 cm, including wristband) consumer-based and wrist-worn wearable activity
monitors. A built-in triaxial accelerometer measures user’s PA characteristics such as
activity intensity throughout the day. Both devices regularly sync with the Fitbit dashboard
via Fitbit mobile application. Fitbit’s dashboard on the app shows user activity progress,
exercise history, and sleep patterns. Additionally, both devices can record and store data,
including steps, activity minutes, distance, EE, exercise, and sleep, for approximately seven
days without syncing with the Fitbit dashboard. Users’ PA data recorded by both devices
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is transferred to the Fitbit application program interface (API) called Fitabase (Small Steps
Lab, San Diego, CA, USA). Fitabase is a research application of the Fitbit devices and
provides data from multiple Fitbit activity monitors in real-time.
2.3. Procedures
Prior to the data collection, the research staff explained the study protocol, and partici-
pants completed the informed consent form. Demographic information was obtained from
participants at the beginning of the data collection session by a self-reported questionnaire.
Once participants completed the demographic questionnaire, research staff measured
the anthropometric characteristics of each participant. Height, weight, and waist circum-
ference were measured using a stadiometer (Shorr Productions; Olney, MD, USA), an
electric weight-scale (Seca, Model 770; Hamburg, Germany), and a tape measure (Gulick II,
Gays Mills, WI, USA), respectively. To avoid measurement error, the research staff mea-
sured all the anthropometric characteristics three times. Body Mass Index (BMI; kg/m2)
was calculated based on the measured height and weight. Following the anthropometric
measures, participants were instructed how to properly wear two activity monitors (i.e., FF
and FF2), then wore both devices on the non-dominant wrist for 14 consecutive days except
while charging the devices and performing aquatic activities. All participants switched the
wearing positions of the FF and FF2 (i.e., top and bottom of the wrist) when both devices
had to be removed and worn during the data collection period. Throughout the 14-day
period, participants recorded time when they removed devices and time when they slept
using an Activity/Sleep Log Sheet.
2.4. Data Processing
Once participants completed the 14 days of instructed wear time, the activity intensity
data measured by FF and FF2 were downloaded via the Fitabase. Using Fitbit’s proprietary
algorithm, the acceleration data recorded by the FF and FF2 is converted into activity counts
(i.e., SED = 0, light PA (LPA) = 1, Moderate PA (MPA) = 2, and Vigorous PA (VPA) = 3). The
activity count data was then exported via Fitabase in 60-s sampling intervals (epochs) for
the subsequent data processing. The activity counts data of the FF and FF2 were merged
and aligned by participant ID, date, and time into a single dataset. The non-wear time and
sleep time were excluded from the single dataset using the self-reported activity/sleep log.
The current study only included the data with the valid time during waking hours of each
day for statistical analyses.
2.5. Statistical Analysis
Pearson product-moment correlation was used to determine the linear relationship
between FF and FF2 in the overall estimation of SED and PA. Additionally, mean absolute
percent errors (MAPEs) were calculated to determine the degree of FF2’s measurement
agreements for SED and PA estimates compared to the FF. Bland-Altman (BA) Plots were
used to present the agreement between FF and FF2 as well as evaluate any potential
systematic biases in SED and PA. Pitman’s Tests for the difference between two correlated
variances were performed to determine the equality of the variances in SED and PAs
estimates between the two devices. To determine the equivalence between FF and FF2, this
study performed equivalence tests. Ultimately, the equivalence was determined if the 90%
CIs of the FF2’s SED and PA estimates fall within the ±10% equivalence zone (EZ) of the
estimates from the FF. However, there is no evidence of the universal acceptable EZ range
of the FF. Thus, the EZs were increased by 5% (i.e., 15%, 20%, and 25%) until equivalence
was reached as well as we calculated the exact ranges of EZ that allows accepting the
equivalence between FF and FF2. Data were analyzed using Stata 14 software (StataCorp
LLC, College Station, TX, USA) and SAS 9.4 software (SAS Institute, Cary, NC, USA).
Statistical significance was determined at p < 0.05.
Int. J. Environ. Res. Public Health 2021, 18, 2716 4 of 11
3. Results
The mean age (±SD) of participants was 23.9 ± 0.8 years. There was no significant
difference in age and wear time between males and females (Age: p = 0.28; Wear time:
p = 0.33). Body mass index (BMI) for males and females were 27.8 ± 3.9 kg/m2 and
22.6 ± 2.2 kg/m2, respectively. Participants’ demographic information is summarized
in Table 1.
Table 1. Characteristics of study participant by gender, Mean (SD) or percent.
Characteristics Total (N = 33) Male (N = 11) Female (N = 22)
Age (years) 23.9 (0.8) 24.1 (0.8) 23.8 (0.8)
Race (%)
White 94% (n = 31) 91% (n = 10) 95% (n = 21)
Other 6% (n = 2) 9% (n = 1) 5% (n = 1)
Weight (kg) 74.8 (15.4) 91.3 (14.6) 66.6 (6.9)
Height (cm) 174.8 (8.2) 181.3 (8.1) 171.6 (6.2)
BMI (kg/m2) 24.3 (3.7) 27.8 (3.9) 22.6 (2.2)
Wear time (min/day) 1074 (174) 1116 (210) 1056 (174)
We found very strong correlations (r > 0.95, p < 0.01) for SED and PA estimates between
FF and FF2 (Figure 1).
Figure 1. Relationship between FF and FF2 in estimating time spent in SED and PA. SED: Sedentary behavior; LPA: Light
physical activity; MPA: Moderate physical activity; VPA: Vigorous physical activity, MVPA: Moderate-to-vigorous physical
activity; TPA: Total physical activity; *: p < 0.05.
The mean difference and MAPE values of SED and PA estimates between FF and
FF2 are presented in Table 2. In general, the FF2 slightly underestimated SED time (mean
difference: 6 min/day; 95% CI: −0.7 to 12.7) and overestimated LPA time (mean difference:
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−6.3 min/day; 95% CI: −11.8 to −0.7). The values of MAPE between FF and FF2 were
relatively small (MAPE range: 0.1%–3.1%).
Table 2. Mean differences and Mean Absolute Percent Errors (MAPE) of SED and PA between FF and FF2.
Intensity FF (SD) FF2 (SD) Mean Difference (SD) 95% CI MAPE
SED 837.2 min (183.3) 831.1 min (179.9) 6.0 min (18.9) −0.7 to 12.7 0.7%
LPA 206.5 min (48.4) 212.8 min (54.6) −6.3 min (15.6) −11.8 to −0.7 3.1%
MPA 16.7 min (13.1) 16.5 min (13.7) 0.2 min (2.6) −0.7 to 1.2 1.2%
VPA 15.6 min (10.9) 15.6 min (10.8) −0.01 min (2.9) −1.0 to 1.0 0.1%
MVPA 32.3 min (19.3) 32.1 min (19.9) 0.2 min (4.7) −1.5 to 1.9 0.6%
TPA 238.8 min (59.4) 244.9 min (66.4) −6.0 min (18.9) −12.7 to 0.7 2.5%
SD: Standard deviation; CI: Confidence interval; SED: Sedentary behavior; LPA: Light physical activity; MPA: Moderate physical activity;
VPA: Vigorous physical activity, MVPA: Moderate-to-vigorous physical activity; TPA: Total physical activity.
Figure 2 presents Bland-Altman (BA) Plots on the mean differences and 95% limits
of agreements between SED and PA estimates from the FF and FF2. BA plots showed no
apparent bias for the agreement and variance in SED and PA estimates between FF and
FF2, except for LPA and TPA estimates. The results from the Pitman’s Test were r = −0.4
(p = 0.02) for LPA and r = −0.37 (p = 0.03) for TPA, indicating that the FF2 increasingly
overestimated LPA and TPA compared to the FF as mean volume of LPA and TPA increased.
Figure 2. Cont.
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Figure 2. Bland-Altman plot comparing estimates of SED and PA between FF and FF2. Dashed lines show 95% limits of
agreement (±1.96 standard deviation); SED: Sedentary behavior; LPA: Light physical activity; MPA: Moderate physical
activity; VPA: Vigorous physical activity, MVPA: Moderate-to-vigorous physical activity; TPA: Total physical activity;
*: p < 0.05.
Results from the equivalence tests are presented in Figure 3. The calculated 90% confi-
dence interval (CI) of the estimate in SED from the FF2 (90% CI = 778.1 to 884.2 min/day)
was within ±10% EZ (10% EZ = 753.5 to 920.9 min/day, actual EZ = ±7.1%) of the SED
estimate from the FF. Additionally, the 90% CI in LPA and TPA estimates (LPA = 196.7 to
228.9; TPA = 225.3 to 264.4) from the FF2 fell within ±15% EZ (LPA = 175.5 to 237.5, actual
EZ = ±10.9%; TPA = 203 to 274.7, actual EZ = 10.8%) of the estimates from the FF. The
EZ of MPA and VPA estimates from the FF were established ± 30% (11.7 to 21.7 min/day,
actual EZ = ±25.6%) and ±25% (11.7 to 19.5 min/day, actual EZ = ±20.5%), respectively,
which included the 90% CI of the MPA and VPA estimates from the FF2 (12.4 to 20.5;
12.4 to 18.8 min/day). Additionally, the 90% CI of the moderate-to-vigorous PA (MVPA)
estimate (26.3 to 28 min/day) from the FF2 fell within ±20% EZ (25.9 to 38.8 min/day,
actual EZ = ±18.9%) of the estimate from the FF.
Figure 3. Cont.
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Figure 3. Equivalence testing for SED and PA. CI: Confidence interval; AEZ: Actual equivalence zone; EZ: Equivalence
zone; SED: Sedentary behavior; LPA: Light physical activity; MPA: Moderate physical activity; VPA: Vigorous physical
activity, MVPA: Moderate-to-vigorous physical activity; TPA: Total physical activity; Vertical dashed lines show the actual
bounds within which the FF2 is statistically equivalent to the FF for SED and PA estimates.
4. Discussion
The current study examined the inter-device reliability between the FF and FF2 in
estimating time spent in SED and PA during a free-living condition over fourteen days.
Overall, our results indicated that the FF2 could provide similar estimates of SED and
PA compared to the FF during a free-living condition. More specifically, there was a
strong positive relationship, relatively low measurement discords, and no apparent bias for
agreement between the FF and FF2 in classifying SED and MVPA in a free-living condition.
Previous research has shown strong positive correlations between the FF and research-
grade accelerometer in their estimates of SED and MVPA [20]. With the established validity
of the FF in mind, our findings of high inter-device agreement between the FF and FF2 also
suggest that the FF2 can accurately classify SED and MVPA. Given the frequent updates
to Fitbit models, our findings suggest that the FF and FF2 can be interchangeably used to
measure SED and MVPA for large cohorts and longitudinal research in measurement and
intervention during a free-living setting.
An important finding of this study was that both FF and FF2 could be comparably
used as PA measurement tools in research, aiming to investigate time spent in SED and
MVPA. The self-monitoring by survey tools could be influenced by the responders’ social
desirability and recall bias [21]. For this reason and with advances in wearable technolo-
gies, accelerometry-based activity monitors such as Fitbit have emerged as popular device
for measuring PA. A few previous studies indicated that the FF can provide relatively
accurate SED and MVPA estimates under free-living conditions [20,22,23] A recent study
by Redenius et al., reported that the FF yielded similar SED estimates with low measure-
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ment error (mean difference = 37 min/day, p = 0.21, mean absolute percent error = 6.8%)
compared to ActiGraph GT3X+ accelerometer in healthy adults [20]. In addition, other
previous studies revealed that the FF overestimated MVPA time by 3% in healthy young
adults (age range: 19 to 37) [23] and 10% in older adults (age: 65.6 ± 6.9 years; the rate of
cardiac patients: 58.9%) [22] when compared to the ActiGraph accelerometer. Given the
recommended acceptable mean errors are within 10% under free-living [24,25] and 20% for
clinical purposes [26], the FF would be considered a valid PA measurement tool to assess
the amount of MVPA in adults. With time, however, the manufacturer replaced the FF with
FF2 for offering more features, such as automatic exercise recognition and call notification,
and convenience through enhancements made to existing configurations. Since the specifi-
cations within the Fitbit’s activity tracker product line are similar, the agreement between
the FF and FF2 is important to increase the internal validity and reliability of measurements
in studies using both FF and FF2. In this regard, we found a strong agreement evident
between the FF and FF2 for the derived SED and MVPA estimates. Moreover, the strong
inter-device agreement would enable harmonized comparisons of PA data across studies
using either the FF or FF2 [27]. Therefore, findings on the validity of FF from previous
studies and strong correlations and measurement agreements observed in the present study
indicated that both FF and FF2 are promising PA measurement tools to estimate time spent
in SED and MVPA in PA epidemiological research.
Another important finding was that the FF2 had a systematic bias in estimating LPA
in comparison with the FF. More specifically, the FF2 increasingly overestimated LPA
compared to the FF as the mean volume of LPA increased (r = −0.4, p = 0.02; Figure 2).
Additionally, the overall mean bias of the FF2 was 6.3 min/day (95% CI: −11.8 to −0.7)
that might lead to the misclassification for SED (Table 2 and Figure 2). It is speculated that
either FF or FF2 might capture relatively low or high magnitudes of wrist acceleration for
SED or LPA of some participants (e.g., typing or standing) during a free-living condition.
Accordingly, the observed difference for the LPA estimate between the FF and FF2 might
influence the difference for the SED estimate. However, the mean bias for LPA did not
significantly impact the agreement of SED estimates between the FF and FF2 under a
free-living condition. It is noteworthy that the equivalence test demonstrated the FF2’s LPA
estimate was equivalent to the FF at ±15% equivalence zone (EZ). The equivalence testing
provides a direct evaluation for measurement agreement between FF and FF2; 15% to 20%
error can be an acceptable error for equivalence depending on the measurement purposes
or populations [28]. Moreover, we calculated the actual bounds within which the FF2 is
statistically equivalent to the FF for LPA estimates by using the equivalence testing. The
calculated actual EZ was ±10.9%, indicating the measurement discord of the FF2 for LPA
was less than 10.9% compared to the estimate from the FF. Thus, the FF2 is still comparable
to the FF in estimating overall LPA time.
It is noteworthy that the FF underestimated time spent in LPA against a research-grade
accelerometer under free-living conditions. The study by Dominick et al., reported that the
FF significantly underestimated the daily proportion of LPA time compared to the hip-worn
ActiGraph GT3X+ (mean difference: −34.0 ± 3.0%, p < 0.001, Cohen effect size = 6.9) in
young adults (age range: 19 to 37 years) [23] A study with pregnant women (age range:
32.7 ± 4.2 years) also showed the FF significantly underestimated time spent in LPA (mean
difference: 25.6 ± 38.7 min/day, p = 0.02) in comparison with ActiGraph GT3X+ [29]. One
possible explanation is that the FF may not consider the short bouts of activity by frequent
breaks or slower motions as LPA [30]. It is speculated that the proprietary Fitbit algorithms
were geared toward capturing the higher bouts of activity. However, it is not known how
the Fitbit algorithms calculate time spent in SED and PA and how these algorithms may
change over time. Considering our finding that the FF2 increasingly overestimated LPA
compared to the FF as mean volume increased, the ability to estimate LPA was likely
improved in the FF2. Therefore, it would be valuable to evaluate the validity of FF2 in
estimating LPA in future research.
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The observed high inter-device agreement of the FF in the current study also under-
lines that Fitbit can be a PA measurement tool in large-scale prospective studies involving
multiple measures throughout follow-up periods. To date, research-grade accelerometers
have been widely used to gain insight into activity levels among various populations
in a large cohort and longitudinal research, such as the National Health and Nutrition
Examination Survey [31]. Unlike the research-grade accelerometer, Fitbit frequently re-
leases new devices on the commercial market, replacing older models. In other words,
it can be unavoidable to include varying models of Fitbit in a longitudinal study. In this
regard, Fitbit devices could be utilized extensively to measure PA in longitudinal studies,
regardless of the model, if the inter-device agreement is established across Fitbit models.
The current study found that there was a high inter-device agreement between Fitbit
models with similar specifications. Additionally, this finding is consistent with a previous
systematic review that high inter-device agreement for PA measurements between Fitbit
models [32]. Accordingly, the use of varying Fitbit models as PA measurement tools may
be feasible in longitudinal studies. Moreover, allowing participants to choose a preferred
model of Fitbit would be more practical and better in terms of usability and adherence to
wearing the device for a long-term period. Supporting this, a recent large cohort study
called All of Us Research Program measures PA characteristics of the participants who
use their own Fitbit device without restricting a particular model of the device. In light
of the established high inter-device agreement, the current study could support the idea
that the use of various Fitbit devices is feasible for tracking PA characteristics in large-scale
longitudinal studies.
Furthermore, most Fitbit devices are relatively inexpensive, simple, and convenient
compared to research-grade accelerometers. Additionally, nearly all Fitbit devices are
popular to varying age groups and worn on the wrist, which improves participants’ ad-
herence to wearing time over prolonged periods [33]. These characteristics, along with
the FF’s high inter-model agreement observed in this study, support that Fitbit devices
show excellent potential for use in intervention studies that may require high compliance
of wearing activity monitors as either an intervention or a measurement tool, regardless of
model generations. Additionally, many researchers and clinicians want to obtain the data
ready for analysis directly from the activity tracker. In this regard, Fitbit offers a relatively
straightforward web-based database/dashboard to aggregate and process data from the
FF and FF2 without additional data processing. In light of the established inter-device
agreement and extended advantages, the FF and FF2 can be a good choice for use in clinical
studies, aiming to assess activity intensity that occurs all day for a long-term duration.
This study has several strengths that include assessing PA behaviors for 14 consecutive
days and the high adherence to wearing time (Table 1). Most previous studies have
assessed SED and PA estimates using Fitbit devices under a free-living condition for 2
to 7 days [6,8,20,23]. The longer duration of the measurement is critical for determining
the reliability of PA measurement because it would more likely cover a variety of activity
patterns, which may have enabled a more valid test of the inter-model agreement between
the FF and FF2. Additionally, our participants were asked to wear the FF and FF2 all day,
except for charging and aquatic activities, for the rigorous assessment. As a result, the
observed average wear time was 1074 ± 174 min/day (Table 1). The minimum burden
of wearing the light-weighted devices might enable high adherence to wearing time in
our participants [33,34]. Consequently, the current study was able to obtain reliable data
regarding the inter-device agreement between the FF and FF2. This study is not without
limitations. The generalizability of the findings from the current study could be limited
due to the relatively small size and homogenous characteristics of our sample.
5. Conclusions
In conclusion, the Fitbit Flex 2 (FF2) is comparable to the Fitbit Flex (FF) in its ability to
estimate SED and MVPA. However, there was not a strong agreement between the FF and
FF2 for LPA estimate. The FF is a valid and reliable activity monitor and has been widely
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used in estimating SED and MVPA and promoting PA across all ages and populations.
Although the FF is a valid activity monitor in estimating SED and MVPA, Fitbit’s frequent
product updates may limit its utilization in longitudinal studies. In our study, the observed
agreement between the FF and FF2 indicates little to no significant difference for SED and
MVPA estimates between model generations. Thus, both FF and FF2 can concurrently be
used, or the predecessor of Fitbit could be replaced with newer models of Fitbit devices
without compromising the validity of SED and MVPA measurement in observational and
clinical research.
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